Syndax Pharmaceuticals, Inc., was founded in 2005 to extend and improve the lives of cancer patients by developing and commercializing novel therapies.
Our vision is boldâ€"to modify the tumor phenotype, allowing for new therapeutic opportunities that restore or extend the benefit of targeted therapies.
Our vision is practicalâ€"to develop effective regimens that have broad commercial potential by optimizing features important to patients, physicians, and payers.
